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Introduction
Diabetes care is expensive. The greater proportion of overall 
expenditure relates to the costs of managing the morbidity 
associated with the long-term, end-organ complications of 
diabetes.1 In the face of the predicted rise in the prevalence 
of type 2 diabetes,2 effective interventions to restore and 
maintain target glycaemia make good clinical and economic 
sense.
Several landmark clinical trials have demonstrated that 
the normalisation of glucose levels is critical for protecting 
patients with type 2 diabetes from long-term complications.3-6
Most patients will require progressively intensified glucose-
lowering medication to reach and maintain target glycaemia, 
as type 2 diabetes mellitus is a progressive condition in 
which glycaemia deteriorates over time.7-9
The Society for Endocrinology, Metabolism and Diabetes 
of South Africa (SEMDSA) and the American Diabetes 
Association (ADA) recommend that the goal of glucose-
lowering therapy is a haemoglobin A1c (HbA1c) level of 
< 7%, and the re-evaluation of therapeutic regimens if HbA1c 
measures are consistently ≥ 7%.7-9
In patients with type 2 diabetes on a treatment regimen 
of maximum oral hypoglycaemic agents (OHAs), an HbA1c 
measure of ≥ 7% should act as a trigger for the timely 
initiation of insulin therapy to effect good glycaemic 
control.7-9
A slow transition from maximum OHA treatment to 
insulin therapy, to achieve target glycaemia, may result in 
expensive-to-manage, long-term complications of type 
2 diabetes mellitus, which translates to an increase in the 
burden of the disease.10,11
Abstract 
Background: Clinically effective interventions that could reduce diabetic patients’ risk of long-term complications are 
needed to contain the rising cost of diabetes care associated with the increasing prevalence of this condition. Good 
glycaemic control needs to be rapidly attained and maintained by the appropriate initiation and adjustment of glucose-
lowering therapy. In patients with insulin-requiring type 2 diabetes who are not at goal glycaemia, this translates to the 
initiation and intensification of insulin therapy. The aim of this study was to evaluate the appropriateness of the initiation of 
insulin therapy in patients with poorly controlled insulin-requiring type 2 diabetes.                                                                                                   
Method: This descriptive retrospective study evaluated treatment regimens, dose adjustments and glycated haemoglobin 
A1c (HbA1c) measurements extracted from records of patients with type 2 diabetes suitable for inclusion. The observation 
period spanned the 24 months retrospective to study start. Data collected were transcribed into a spreadsheet suitable for 
statistical analysis.
Results: Of the overall cohort of patients with insulin-requiring type 2 diabetes (n = 131), only 45.8% (n = 60) were 
commenced on insulin during the observation period, of whom 51.7% had subsequent adjustment of insulin dosage. Mean 
HbA1c at insulin initiation was 10.29% (± 2.42), and 10.63% (± 1.93) after adjustment of insulin dose (p-value > 0.05). Of 
those who remained on oral glucose-lowering therapy (n = 71), 57.7% had no change in medication dosage throughout the 
study period. Overall, 81.35% remained  ≥ 1% above goal HbA1c by the end of the study period.
Conclusion: This study found a discrepancy in the appropriate use and adjustment of insulin therapy according to metabolic 
status.
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Timely initiation of insulin therapy is defined as the 
commencement of insulin in patients with type 2 diabetes 
who are not at recommended target glycaemia, despite 
taking maximum doses of OHAs.8,10,12 Such patients are 
deemed “insulin-requiring”.
A maximum dose of OHAs is defined as metformin 2 550 mg 
daily, or the maximum tolerated dose, together with either 
glibenclemide 15 mg daily, or gliclazide 320 mg daily.9,13
The aim of this study was to analyse prescribing practices 
for the management of patients with type 2 diabetes in 
terms of metabolic parameters and treatment regimens, as 
observed from patient records. The purpose was to assess 
and evaluate the appropriateness of the initiation of insulin 
therapy in patients with poorly controlled insulin-requiring 
type 2 diabetes.                                                                                                   
Method
This descriptive retrospective study analysed data 
extracted from files of patients with insulin-requiring type 
2 diabetes attending the medical outpatients’ department 
of a large regional public sector hospital in KwaZulu-
Natal. Approximately 1 500 patients with chronic medical 
conditions are seen in a month at this medical outpatients’ 
department, of whom approximately 30% have diabetes. 
Attending medical officers review these patients every six 
months, and prescribe ongoing treatment.
Records of patients with type 2 diabetes mellitus were 
eligible for inclusion if patients made at least four visits to 
the study clinic during the observation period, if the most 
recent visit occurred within six months prior to start of the 
study, if patients had HbA1c measures of ≥ 7% on two or 
more occasions, and ≥ 3 months apart during the same 
period.
The period of observation was the 24 months retrospective 
to the start of the study.
The maximum number of files meeting the inclusion criteria 
(n = 247) was sampled over a one-month period from the 
registry of records of all diabetic patients who attended the 
study site over the same period (n = 463).
Of these, files of all patients commenced on an insulin 
regimen during the observation period, and files of 
all patients on maximum OHA therapy over the same 
period, were identified. Following consultation with a 
biostatistician, it was decided to sample 50% of the files 
that met the inclusion criteria. Patient files ending in an even 
number were selected, and made up the final study sample 
(n = 131). 
Treatment regimen information and dose adjustments were 
collected and recorded, together with HbA1c measurements 
which were obtained from the designated hospital laboratory 
database.
The hospital laboratory method of HbA1c measurement is 
by ion-exchange, high-performance liquid chromatography, 
with a co-efficient variation of 1.15% in line with the 
Diabetes Control and Complications Trial standardisation of 
HbA1c assays that have an acceptable co-efficient variation 
of < 4%.14 
Patient data were recorded at five time points:
•	 Time 1: Most recent clinic visit within the six months 
retrospective to study start
•	 Time 2: Time 1 minus six months
•	 Time 3: Time 1 minus 12 months
•	 Time 4: Time 1 minus 18 months
•	 Time 5: Time 1 minus 24 months.
Age, sex, race, and concomitant conditions were recorded, 
but were only used for the demographics and description of 
the study cohort. 
Data collected were entered into an Excel® spreadsheet, 
and then transcribed into a spreadsheet package suitable 
for statistical analysis.                       
In this study, descriptive analysis was performed in order 
to report and summarise the findings. Frequency counts, 
percentages and 95% confidence intervals were reported 
for categorical variables. Summary statistics such as mean, 
standard deviation and range were reported for quantitative 
variables. A paired t-test was performed to compare the 
mean HbA1c level at initiation of the insulin therapy, with the 
HbA1c level at the most recent clinic visit. A p-value value of 
< 0.05 was considered to be statistically significant.                                  
Approval to conduct this study was granted by the University 
of KwaZulu-Natal, and by the hospital management.   
Results
Two hundred and forty-seven patient records were suitable 
for extraction of data, and 131 made up the final study 
sample. Of these, 54.2% (n = 71) were of patients on 
maximum OHAs, and 45.8% (n = 60) of patients commenced 
on insulin within the 24-month observation period (Table I). 
In total, 338 HbA1c levels were measured over the observation 
period; a mean of 2.58 (± 0.67) and 2.53 (± 0.65) for the 
OHA and insulin subsets, respectively. Patients had several 
measurements of HbA1c  ≥ 7% before having insulin initiated 
[1.6 (± 0.80)] (Table II).
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Of the overall cohort, the only change in oral therapy was 
an adjustment to maximum tolerable doses for metformin 
(22.9%), and not intensification of oral therapy (Table III). 
Of the OHA subset, 57.7% did not have any adjustment of 
medication dosage throughout the observation period. 
By the most recent visit, the majority of the overall cohort 
remained at suboptimal glycaemic control (Table IV).
Discussion
Adequate metabolic control is key to reduced risk of 
diabetes complications.3-6 Both SEMDSA and the ADA 
recommend the goal of glucose-lowering therapy to be an 
HbA1c level of < 7%, and the re-evaluation of therapeutic 
regimens if HbA1c measures remain consistently ≥ 7%.
7-
9 Thus, the appropriate use and adjustment of glucose-
lowering medication according to metabolic parameters, 
HbA1c, is critical for good glycaemic control.
Initiation of insulin  
Several studies and standard treatment policies recommend 
the initiation of insulin in patients with type 2 diabetes on 
maximum dual oral therapy when the HbA1c level remains 
consistently ≥ 7%.5,7-9
While insulin is recommended in patients not achieving 
glycaemic control on maximum OHAs, this study 
demonstrated that only a small proportion of patients had 
actually been commenced on insulin therapy. Of the overall 
cohort, 45.8% were commenced on an insulin regimen 
during the 24-month observation period, while 54.2% 
remained on maximum OHAs, despite having a mean 
HbA1c above 7% (9.58 ±1.71%) by the end of the study 
observation period.
These proportions are comparable to those shown by 
Kirkman et al15 where, of 275 insulin-requiring diabetic 
patients, only 40% were taking insulin. Similarly, upon 
analysis of pharmacy data from a United Kingdom database, 
Fox et al16 showed that, at an HbA1c cut-off of > 7.5%, 41% 
and 52% of patients with insulin-requiring type 2 diabetes 
were still on ≥ 2 OHAs by 1998 and 2002, respectively. 
In a similar study, also by analysis of data from a UK 
database, Rubino et al17 estimated that if followed up for 
five years, only 25% of patients with insulin-requiring type 
2 diabetes will have insulin initiated within 1.8 years, and 
50% within 4.9 years. By comparison, in the 2005 Canadian 
Evaluation study,18 only 12% of insulin-requiring type 2 
diabetic patients had insulin introduced for better glycaemic 
control. 
Two South African studies reported that most patients with 
diabetes were found to be insulin requiring, yet remained 
at poor glycaemia because of frequent rare modification 
Table I: Cohort characteristics
Characteristic Cohort
Frequency Percentage (%)
Overall cohort 131 100
Maximum OHAs 71 54.2
Insulin 60 45.8









Dyslipidaemia  63 47.6
Ischaemic heart disease 36 27.6
* Age given as mean ± standard deviation 
Table II: Metabolic characteristics of cohort
Parameter OHA Insulin Cohort
Mean SD Mean SD Mean SD
Number HbA1c per 
point
2.58 0.67 2.53 0.65 2.56 0.66
Number HbA1c 
before change to  
insulin
1.60 0.80
HbA1c Vo* 8.56 1.63 10.02 3.18 9.28 2.4
HbA1c Vi** 8.39 1.93
*** 10.29 2.42**** 9.22 2.22
HbA1c Vr***** 9.58 1.71 10.63 1.93
**** 9.75 1.87
* Beginning of observation period, ** Change of medication viz. initiate insulin or change 
in oral hypoglycaemic dose, *** Oral hypoglycaemic doses adjusted to maximum tolerable 
dose for metformin and not actual intensification of oral therapy, **** p-value difference of 
glycaemic control between Vi and Vr = 0.312, ***** Most recent visit (“final” visit)
Table III: Medical regimen adjustment characteristics
Parameter (24-month observation 
period)
Percentage of  
overall cohort
No change in therapy at all 31.3
Change to tolerable OHA dose 22.9
Change in insulin dose after initiation 51.7
No change in insulin dose after initiation 48.3
Table IV: Glycaemic status of cohort at the end of study
HbA1c Total cohort OHA
arm
Insulin arm
< 7%* 17.7% 10.3% 23.1%
≥ 7%** 83.3% 89.7% 76.9%
> 8% 81.3%*** 76.1%*** 86.7%e
* Optimal or goal glycaemia,  ** Suboptimal glycaemia, *** Percentage of suboptimal group 
with HbA1c  ≥ 1% above goal 
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of glucose-lowering medications and insulin not being 
prescribed.19,20 
Early addition of insulin is recommended as an efficient 
way of achieving target glycaemia, and could lead to 
a substantial decrease in patients’ long-term risk of 
developing complications.3,21,22 
In this study, the mean level of HbA1c at which insulin was 
initiated was 10.29% (± 2.42). 
Late introduction of insulin therapy has been demonstrated 
by several international studies,10,12,23 where glucose-
lowering action was triggered by an HbA1c level of ≥ 9%, 
while Dailey25 demonstrated that the trigger for intensifying 
treatment was an HbA1c ≥ 10%. 
Harris et al10 further demonstrated that at the time of 
initiation of insulin, 74% of his study cohort already had 
one diabetes-related complication, suggesting a prolonged 
period of above-target HbA1c levels.
According to Hirsch et al and Spellman,24-26 an HbA1c level of 
≥ 1% above goal is a clear indication for the introduction of 
insulin in patients with type 2 diabetes who fail to respond 
to maximum OHA therapy. 
Of those patients who remained on OHAs throughout 
this study, the mean HbA1c measured at the end of the 
observation period (9.58 ± 1.71%) was ≥ 1% above goal, 
and is suggestive of a delay in the initiation of insulin 
according to metabolic parameters. 
The mean level of HbA1c at which insulin was commenced 
(10.29 ± 2.42%), together with the number of HbA1c levels 
≥ 7% (1.60 ± 0.80) that were considered before insulin 
was initiated, is also suggestive of a delay in making the 
necessary transition from OHA therapy to insulin therapy 
using HbA1c levels as a guide. 
Rapid attainment of good glycaemic control is critical 
in improving outcomes in patients with diabetes. It is 
recommended that, in patients with insulin-requiring type 
2 diabetes, insulin should be started within three to six 
months, if combination oral therapy cannot achieve HbA1c 
goals.27 
In this study, the slow transition from OHA therapy to insulin 
was evidenced by the 57.7% of patients on maximum OHA 
therapy who did not have any alteration to their therapy over 
the total 24-month period of observation. 
Such findings are not peculiar to this study. Harris et al10 
showed that healthcare professionals waited an average 
of 9.2 years before initiating insulin in patients with type 
2 diabetes mellitus, at which point HbA1c levels were well 
above target, and resultant diabetes complications had 
begun to develop. 
Delayed introduction of insulin has also been reported by 
Nathan,11 who found that patients had diabetes for 10-15 
years before being treated with insulin.
Intensification of therapy
Appropriate medication change, adjustment and titration 
represent the major strategies for lowering glucose levels, 
and are necessary for effective and successful diabetes 
care.28
Of the subset of patients commenced on insulin, 51.7% had 
an adjustment of insulin dose, including the addition of a 
second insulin type, while 48.3% did not have any change in 
dose after insulin was commenced. More than half (57.7%) 
of the OHA subset did not have any change in therapy for 
the duration of observation, despite having a mean HbA1c 
above 7% (9.58 ± 1.71%) by the most recent visit.
Several international studies have shown that the frequency 
of dose adjustment of medication was less than expected 
for patients with inadequate glycaemic control. Reports of 
the proportion of patients with above-goal HbA1c levels, who 
did not have intensification of anti-diabetic therapy, varied 
from 23-54%.23,29,30 
While proportions are not reported, an audit of primary 
care services in Cape Town revealed that fewer than half 
of the clinic visits resulted in any change of diabetes 
management.31 
Patients attending this study clinic have their HbA1c levels 
measured a month prior to their visit to the doctor. This, 
together with the fact that these HbA1c results are easily 
retrievable from the laboratory database, presents an 
opportunity to assess and optimise diabetes treatment at 
every doctor’s visit.
In this study, there was no statistically significant change 
in mean HbA1c level at the time of initiation of insulin 
(10.29 ± 2.42%) and the mean HbA1c level at the end of 
the observation period (10.63 ± 1.93%) (p-value = 0.312), 
suggesting that although there was some intensification of 
hypoglycaemic treatment, it was not adequate to achieve 
target glycaemic control. 
While the practice of the study clinic is to refer patients 
initiated on insulin to their local primary health clinic for 
up-titration of doses on a weekly basis, the persistently 
above-normal HbA1c levels at follow-up clinic visits suggest 
a deviation from this prescribing practice. 
In this study, the frequency of intensification of therapy was 
less than expected, as evidenced by the low proportion 
of medication adjustment in patients not meeting 
recommended therapeutic goals. 
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Diabetes care measures  
The HbA1c assay has become the gold standard 
measurement of chronic glycaemia, and is used as an index 
of mean plasma glucose levels.14 It is recommended that 
the HbA1c is measured every six months to guide clinicians’ 
treatment decisions.7-9,14  
In total, 338 HbA1c levels were measured over the 24-month 
observation period, giving a mean number of HbA1c 
measurements for the OHA and the insulin subsets as 2.58 
(± 0.67) and 2.53 (± 0.65), respectively. 
This frequency of HbA1c measurement suggests a favourable 
level of quality measure in terms of HbA1c testing. However, 
this does not necessarily translate into adequate metabolic 
control, as evidenced by the above-goal mean HbA1c (9.75 ± 
1.87%), and the high proportion of patients with suboptimal 
control (83.3%) at the final visit of the observation period.  
In South Africa, Van Zyl and Rheeder1 showed that annual 
HbA1c measurements rose from 70% of patients tested, to 
94% tested after the implementation of a physician diabetes 
education programme, and reported that such findings were 
similar to the proportion of diabetes care measures carried 
out by American clinics.  
In a study conducted by Grant12 to assess the quality of 
care provided at clinics in America, overall levels of quality 
measure of HbA1c were good, yet quality of care was 
deemed low in terms of proportions of patients not meeting 
goal glycaemia. Such findings were confirmed in Canada by 
Harris and Worrall,32 and in the UK by Fox et al.16
End-study glycaemia
Both SEMDSA and the ADA recommend the goal of therapy 
to be an HbA1c level of < 7%.
7-9
In this study cohort, the proportion of patients meeting goal 
glycaemia was disappointingly low. Despite the introduction 
of insulin, 76.9% of this subset remained at suboptimal 
glycaemic control by the end of the observation period, with 
86.7% of these having “final” HbA1c measures ≥ 1% above 
goal HbA1c of < 7%.
Of the patients remaining on maximum OHA therapy, only 
10.3% achieved target glycaemic control, with 76.1% 
having “final” HbA1c measures ≥ 1% above goal HbA1c of 
< 7%. 
These results are comparable with those demonstrated by 
Steyn et al33 in the Western Cape, where 76% of patients 
with type 2 diabetes mellitus had HbA1c levels ≥ 1% above 
the upper limit of normal. 
Similar suboptimal control has been reported by Erasmus 
et al34  in a study conducted in South Africa, in which 
only 20.1% of patients achieved HbA1c levels of < 7%, 
irrespective of sex, duration of diabetes, body mass index, 
educational status, dietary advice, or type of treatment. 
Failure to achieve targets, even once insulin was 
commenced, was shown by Gough et al35 in the UK, and 
Hayward and Manning36 in America. After a mean of two 
years of insulin therapy, Gough et al35 reported that 81% 
of subjects had HbA1c values of > 7%, while Hayward and 
Manning36 reported 60% of subjects had HbA1c levels of 
≥ 8%. 
Limitations
Some limitations have been identified in interpreting the 
findings from this study. A single site was studied, the study 
sample was small, and the results described are those of 
a very specific study cohort, and thus may be subject to 
selection bias.
Conclusion
In this study cohort, a discrepancy in the appropriate use 
and adjustment of insulin therapy according to metabolic 
status was evident, based on analysis of metabolic and 
treatment regimen data extracted from patient files. 
The results of this study demonstrated a slow transition 
from OHA therapy to insulin therapy in poorly controlled 
insulin-requiring type 2 diabetes. Intensification of therapy 
was not adequate, resulting in HbA1c levels remaining well 
above recommended targets, and the majority of patients 
remaining poorly controlled by the end of the observation 
period. Such prolonged exposure to hyperglycaemia may 
increase the risk of developing unwanted, expensive-to-
treat, long-term complications associated with type 2 
diabetes mellitus. 
While barriers to insulin initiation need to be identified 
and addressed, appropriate medication adjustment and 
intensification is critical for good glycaemic control and 
improved patient outcomes, thereby reducing the burden 
of disease. 
The awareness for the timely transition from oral glucose-
lowering therapy to insulin therapy needs to be built into the 
clinical practice of healthcare professionals who manage 
and treat patients with type 2 diabetes mellitus.  
The simple, well-documented practice of using an HbA1c 
level of ≥ 7% as an alert to trigger appropriate adjustment 
of glucose-lowering therapy is recommended. Once this 
awareness to alter therapy has been created, barriers 
to insulin initiation need to be addressed and taken into 
consideration when implementing insulin therapy in patients 
with insulin-requiring type 2 diabetes.
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